SCHEMBL22504483

SCHEMBL22504483

O=C(O[C@@H]1OC(CO)[C@@H](O)C(O)C1O)c1cc(O)c(O)c(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.56
SLC28A3 Q9HAS3 3/20 0.49
TDP1 Q9NUW8 2/20 0.48
TMPRSS2 O15393 1/20 0.48
USP2 O75604 1/20 0.48
PDE5A O76074 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
HMGCR P04035 1/20 0.48
CYP1A2 P05177 1/20 0.48
LCK P06239 1/20 0.48
FYN P06241 1/20 0.48
HSPD1 P10809 1/20 0.48
CYP2C9 P11712 1/20 0.48
CA6 P23280 1/20 0.48
TBXAS1 P24557 1/20 0.48
MAPK3 P27361 1/20 0.48
MAPK1 P28482 1/20 0.48
HSPE1 P61604 1/20 0.48
MAPK14 Q16539 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1315483 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL13456979 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL4416998 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL4620889 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL1263104 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL16906157 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL11986810 1.00 AKR1B1 (0.56) AKR1B1SLC28A3TDP1TMPRSS2USP2
SCHEMBL5664342 0.89 EPHX2 (0.55) AKR1B1SLC28A3TMPRSS2USP2PDE5A
SCHEMBL11986813 0.89 SLC28A3 (0.50) AKR1B1SLC28A3TDP1MAPK1PTPN1
SCHEMBL28793347 0.89 TMPRSS2 (0.52) AKR1B1TMPRSS2USP2PDE5ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230320987-A1 LIPID NANOPARTICLES AND LIPOSOMES NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-10-12 US disclosed
US-20200315998-A1 COMPOSITION FOR IMPROVING INTESTINAL BARRIER FUNCTION SUNTORY HOLDINGS LIMITED (JP) 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200315998-A1 COMPOSITION FOR IMPROVING INTESTINAL BARRIER FUNCTION FABP2, SLC10A2, VIP AKR1B1 1240/4885SLC28A3 141/4885TDP1 4632/4885
US-20230320987-A1 LIPID NANOPARTICLES AND LIPOSOMES PHOSPHO1, LIPA, PLIN3 AKR1B1 4047/4885SLC28A3 1241/4885TDP1 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.